Passage Bio reports Q3 net loss of $27.1M; cash runway into Q4 2025, clinical data on track

Passage BIO, Inc.

2023-Q3 EPS reported -$1.56

Cash, equivalents and marketable securities of $132.8M as of Sept 30, 2023; cash runway extended into Q4 2025.
Net loss of $27.1M ($0.49 per share) for Q3 2023, comparable to $26.7M ($0.49) in Q3 2022.
R&D expenses $15.1M; G&A expenses $8.2M, down from $10.7M due to workforce reductions.
Initial safety and biomarker data from three Cohort 1 patients in PBFT02 (FTD-GRN) trial expected in Q4 2023.
GM1 trial (Imagine-1) treating multiple patients at Dose 3; initial safety/biomarker data from Dose 3 expected mid-2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Passage BIO, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $27.1 million, or a net loss of $0.49 per basic and diluted share, EPS $0.49 per basic and diluted share.

Period: the third quarter ended September 30, 2023
Net income: Net loss was $27.1 million, or a net loss of $0.49 per basic and diluted share
EPS: $0.49 per basic and diluted share
Result: reported results

Exact text from the filing

Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-018679

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.